Weight loss can be a challenge, even for those who eat healthily and exercise regularly. But injectable type 2 diabetes ...

The first GLP-1 receptor agonist approved for obesity was liraglutide, marketed in the U.S. as Saxenda, in 2014. However, the ...

Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally ...

Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally ...

There’s been lots of attention on type 2 diabetes drugs recently, especially since they might also be able to support weight ...

Digital health companies faced high advertising costs and focused on returns on investments in the third quarter.

Hims & Hers Health (HIMS) stock gains after its Q3 2024 results as company plans to launch a generic version of Novo ...

The warning applies to the entire class of GLP-1 drugs, including liraglutide (Saxenda, Victoza), semaglutide (Ozempic, Rybelsus, Wegovy), and tirzepatide (Mounjaro, Zepbound). People taking these ...

FDA approved medications included in the study were GLP-1s liraglutide, semaglutide and tirzepatide, and SGLT2s canagliflozin, dapagliflozin, empagliflozin and ertugliflozin. Here are five things to ...

SAN ANTONIO -- Research presented at the ObesityWeek annual meeting included studies on rationing of prescription medications ...

The updated AAP clinical guidelines on obesity treatment recommend offering the full spectrum of care upon initial obesity ...

The millennial-skewed telehealth platform Hims & Hers (HIMS) announced Monday that it will start offering customers a generic version of liraglutide, an older GLP-1 weight loss drug, next year. The ...